Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.74 |
| ▸ | ABL1 | P00519 | 5/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.72 |
| ▸ | SRC | P12931 | 5/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.72 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102234 | 0.93 | EGFR (0.74) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL19314794 | 0.89 | EGFR (0.76) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL12696080 | 0.84 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL1507604 | 0.82 | EGFR (0.87) | EGFRABL1FGFR1SRCPDGFRB | |
| Hydrochloric Acid SCHEMBL1507697 | 0.81 | EGFR (0.85) | EGFRABL1FGFR1SRCPDGFRB | |
| Hydrochloric Acid SCHEMBL8811465 | 0.80 | EGFR (0.74) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5568094 | 0.80 | PDE5A (0.66) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL8871863 | 0.80 | EGFR (0.82) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8871418 | 0.79 | EGFR (0.71) | EGFRFGFR1KDRERBB2MAPK1 | |
| SCHEMBL2100935 | 0.78 | EGFR (0.64) | EGFRABL1FGFR1SRCPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |